Antibody therapy company AbClon announced on the 29th that its CEO Lee Jong-Seo received the Presidential Commendation at the '2024 Government Awards for Healthcare Technology Advancement'.

The Government Awards for Healthcare Technology Advancement, hosted by the Ministry of Health and Welfare, recognize individuals who have made significant contributions to the advancement of healthcare technology in Korea every year. Dr. Lee received the award for his contribution to widely publicizing the excellence of Korean pharmaceuticalㄴ and biotechnology in the global new drug market.

Dr. Lee developed over 80,000 research antibodies through the 'Human Protein Atlas Project', a joint research project of the Royal Swedish Academy of Sciences, by establishing advanced antibody development technology. In particular, his technology transfer achievements include the antibody 'AC101 (Chinese name: HLX22)' for the first-line gastric cancer treatment and an antibody that specifically binds to anti-HER2 (human epidermal growth factor receptor type 2) that is highly expressed in gastric cancer cells.

In addition, AbClon is currently developing a blood cancer CAR-T (chimeric antigen-T) cell therapy equipped with its proprietary antibody and bi-specific antibodies for solid cancers based on the AffiMab platform. These technological advances have been acknowledged through the filing of over 80 domestic and international patents applications.

Dr. Lee said, “About 80% of AbClon’s employees are researchers, and the company is deeply committed to investing in technological advancements,” and “We aim to grow into an innovative pharmaceutical company that can maximize the treatment effect and ultimately achieves a complete cure for patients with intractable cancers.” End